

Proliferative Vitreoretinopathy Therapeutic Pipeline Market Review, H2 2016

Global Proliferative Vitreoretinopathy Drugs and Companies Pipeline Review H2 2016

PUNE, INDIA, September 19, 2016

/EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development for [Proliferative Vitreoretinopathy](#) (PVR), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Proliferative Vitreoretinopathy (PVR) and features dormant and discontinued projects. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Complete Report @ <https://www.wiseguyreports.com/reports/643475-proliferative-vitreoretinopathy-pvr-pipeline-review-h2-2016>

Scope

- The report provides a snapshot of the global therapeutic landscape of Proliferative Vitreoretinopathy (PVR)
- The report reviews pipeline therapeutics for Proliferative Vitreoretinopathy (PVR) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Proliferative Vitreoretinopathy (PVR) therapeutics and enlists all their major and minor projects



- The report assesses Proliferative Vitreoretinopathy (PVR) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Proliferative Vitreoretinopathy (PVR)

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/643475-proliferative-vitreoretinopathy-pvr-pipeline-review-h2-2016>

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Proliferative Vitreoretinopathy (PVR)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Proliferative Vitreoretinopathy (PVR) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Have any query @ <https://www.wiseguyreports.com/enquiry/643475-proliferative-vitreoretinopathy-pvr-pipeline-review-h2-2016>

Table of Content

Proliferative Vitreoretinopathy (PVR) Overview	6
Therapeutics Development	7
Pipeline Products for Proliferative Vitreoretinopathy (PVR) - Overview	7
Pipeline Products for Proliferative Vitreoretinopathy (PVR) - Comparative Analysis	8
Proliferative Vitreoretinopathy (PVR) - Therapeutics under Development by Companies	9
Proliferative Vitreoretinopathy (PVR) - Therapeutics under Investigation by Universities/Institutes	10
Proliferative Vitreoretinopathy (PVR) - Pipeline Products Glance	11
Early Stage Products	11
Proliferative Vitreoretinopathy (PVR) - Products under Development by Companies	12
Proliferative Vitreoretinopathy (PVR) - Products under Investigation by Universities/Institutes	13
Proliferative Vitreoretinopathy (PVR) - Companies Involved in Therapeutics Development	14
Novartis AG	14
Promedior, Inc.	15
RXi Pharmaceuticals Corporation	16
Proliferative Vitreoretinopathy (PVR) - Therapeutics Assessment	17
Assessment by Monotherapy Products	17
Assessment by Target	18
Assessment by Mechanism of Action	20
Assessment by Route of Administration	22
Assessment by Molecule Type	23
Drug Profiles	25
Antisense RNAi Oligonucleotide to Inhibit CTGF for PVR - Drug Profile	25
Product Description	25
Mechanism Of Action	25

R&D Progress	25
Drug to Inhibit TAK1 for Proliferative Vitreoretinopathy - Drug Profile	26
Product Description	26
Mechanism Of Action	26
R&D Progress	26
LD-224 - Drug Profile	27
Product Description	27
Mechanism Of Action	27
R&D Progress	27
PRM-167 - Drug Profile	28
Product Description	28
Mechanism Of Action	28
R&D Progress	28
Small Molecules to Target Hdm2 for Proliferative Vitreoretinopathy - Drug Profile	30
Product Description	30
Mechanism Of Action	30
R&D Progress	30
XOMA-089 - Drug Profile	31
Product Description	31
Mechanism Of Action	31
R&D Progress	31
Proliferative Vitreoretinopathy (PVR) - Dormant Projects	32
Proliferative Vitreoretinopathy (PVR) - Product Development Milestones	33
Featured News & Press Releases	33
Apr 27, 2015: RXi Pharmaceuticals Announces Upcoming Presentations at Leading Partnering and Scientific Conferences	33
May 22, 2014: RXi Pharmaceuticals Granted US Notice of Allowance Covering Self-Delivering (sd-rxRNA) Technology Platform	34
May 07, 2012: Promedior Presents Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting	35
May 01, 2012: Promedior To Present Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting	36
Appendix	37
Methodology	37
Coverage	37
Secondary Research	37
Primary Research	37
Expert Panel Validation	37

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=643475

Continued...

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2020 IPD Group, Inc. All Right Reserved.